Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,633 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumour burden and efficacy of immune-checkpoint inhibitors.
Dall'Olio FG, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N, Robert C, Besse B. Dall'Olio FG, et al. Among authors: robert c. Nat Rev Clin Oncol. 2022 Feb;19(2):75-90. doi: 10.1038/s41571-021-00564-3. Epub 2021 Oct 12. Nat Rev Clin Oncol. 2022. PMID: 34642484 Review.
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial.
Escudier B, Dorval T, Chaput N, André F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, Serra V, Valente N, Le Pecq JB, Spatz A, Lantz O, Tursz T, Angevin E, Zitvogel L. Escudier B, et al. Among authors: robert c. J Transl Med. 2005 Mar 2;3(1):10. doi: 10.1186/1479-5876-3-10. J Transl Med. 2005. PMID: 15740633 Free PMC article.
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L. Ghiringhelli F, et al. Among authors: robert c. J Exp Med. 2005 Oct 17;202(8):1075-85. doi: 10.1084/jem.20051511. J Exp Med. 2005. PMID: 16230475 Free PMC article.
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.
Ménard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taïeb J, Delahaye NF, Flament C, Emile JF, Le Cesne A, Zitvogel L. Ménard C, et al. Among authors: robert c. Cancer Res. 2009 Apr 15;69(8):3563-9. doi: 10.1158/0008-5472.CAN-08-3807. Epub 2009 Apr 7. Cancer Res. 2009. PMID: 19351841 Clinical Trial.
Cyclophosphamide induces differentiation of Th17 cells in cancer patients.
Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, Chaput N, Zitvogel L. Viaud S, et al. Among authors: robert c. Cancer Res. 2011 Feb 1;71(3):661-5. doi: 10.1158/0008-5472.CAN-10-1259. Epub 2010 Dec 9. Cancer Res. 2011. PMID: 21148486 Clinical Trial.
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.
Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E, Robert C. Delyon J, et al. Among authors: robert c. Ann Oncol. 2013 Jun;24(6):1697-703. doi: 10.1093/annonc/mdt027. Epub 2013 Feb 24. Ann Oncol. 2013. PMID: 23439861 Free article.
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.
Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, Vassal G, Eggermont A, Zitvogel L, Chaput N, Paci A. Pautier P, et al. Among authors: robert c. Oncoimmunology. 2013 Feb 1;2(2):e23079. doi: 10.4161/onci.23079. Oncoimmunology. 2013. PMID: 23525192 Free PMC article.
1,633 results